Abstract Details

Title Health State Utility Values in Paediatric Subjects with Partial Onset Seizures (POS) or Primary Generalized Tonic Clonic Seizures (PGTCS) receiving Adjunctive Perampanel

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) Epilepsy/Clinical Neurophysiology (EEG) Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 109

Objective To estimate health-state utility values (HSUVs) according to seizure frequency in paediatric patients with POS or PGTCS.

Background Novel therapies, such as adjunctive perampanel for paediatric patients with POS or PGTCS, must be assessed in terms of cost-effectiveness prior to their adoption within healthcare systems, where effectiveness is commonly measured in terms of quality-adjusted life years (QALYs). HSUVs derived from patient-reported data are commonly used to inform QALYs.

Design/Methods Study 311 (E2007-G000-311; NCT02849626) was a Phase 3, multicenter, open-label single-arm study of adjunctive perampanel oral suspension in paediatric patients (aged 4 to <12) with POS or PGTCS. The EuroQoL 5-Dimension Youth 3-Level (EQ-5D-Y-3L) questionnaire was completed at Baseline, Week 23 and Week 52; utilities were derived using the EQ-5D-3L UK adult value set. Subjects were partitioned into the following health states based on their experience of seizures over a year: seizure free, >= 1 seizure per year (to < 1 seizure per month), >= 1 seizure per month (to < 1 seizure per week), >= 1 seizure per week. HSUVs were estimated using a linear mixed model to account for repeated measurements within each subject.

Results 179 EQ-5D-Y-3L observations from 60 subjects were assigned to a health state. HSUVs were estimated as follows: seizure free (N Obs=15; LS Mean 0.914 [95% CIs 0.587 – 1.240]), >= 1 seizure per year (N Obs=122; 0.620 [0.506, 0.734]), >= 1 seizure per month (N Obs=24; 0.596 [0.338, 0.855]), >= 1 seizure per week (N Obs=18; 0.284 [-0.014, 0.582]).

Conclusions

Increasing seizure frequency is associated with decreasing utility. These estimates can inform cost-effectiveness modelling of perampanel and other therapies aiming to reduce seizure frequency in paediatric patients. Further analysis is warranted once a child-specific value set becomes available.

Authors/Disclosures
Andrew Trigg PRESENTER	Andrew Trigg has received personal compensation for serving as an employee of Adelphi Values.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details